SpringWorks climbs as genetic disorder treatment succeeds in trial

SpringWorks Therapeutics

16/11/2023 14:01

** Shares of drug developer SpringWorks Therapeutics
 SWTX.O  rise ~2% to $22.50 premarket
    ** Co says its drug mirdametinib met the main goal in a
mid-stage trial in patients with Neurofibromatosis type 1 (NF1) 
    ** The drug reduced tumor sizes by 52% in pediatric patients
and 41% in adult patients vs the main goal of minimum of 20%
reduction
    ** NF1 is a genetic condition that causes tumours to grow
along nerves
    ** Up to last close, stock down 15.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))